alfuzosin has been researched along with vardenafil dihydrochloride in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, P; Borer, J | 1 |
| Hauzeur, C; Roumeguère, T; Schulman, C; Vanhaeverbeek, M; Wespes, E; Zouaoui Boudjeltia, K | 1 |
| Belal, F; Borg, H; Fathy, M; Walash, MI; Zayed, S | 1 |
| Eid, MI; El-Shabrawy, Y; Elama, HS; Shalan, SM; Zeid, AM | 1 |
1 review(s) available for alfuzosin and vardenafil dihydrochloride
| Article | Year |
|---|---|
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Prostatism; Purines; Quality of Life; Quinazolines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2009 |
3 other study(ies) available for alfuzosin and vardenafil dihydrochloride
| Article | Year |
|---|---|
Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adolescent; Adult; Advisory Committees; Anti-Infective Agents; Aza Compounds; Cardiovascular Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Drug Approval; Electrocardiography; Fluoroquinolones; Humans; Imidazoles; Impotence, Vasculogenic; Male; Middle Aged; Moxifloxacin; Phosphoric Diester Hydrolases; Piperazines; Prostatic Hyperplasia; Quinazolines; Quinolines; Risk Assessment; Sulfones; Triazines; United States; United States Food and Drug Administration; Vardenafil Dihydrochloride | 2003 |
Simultaneous HPLC determination of alfuzosin, tamsulosin and vardenafil in human plasma and pharmaceutical formulations using time programmed fluorescence detection.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Chromatography, High Pressure Liquid; Drug Compounding; Humans; Male; Prostatic Hyperplasia; Quinazolines; Reference Standards; Reproducibility of Results; Spectrometry, Fluorescence; Tamsulosin; Vardenafil Dihydrochloride; Vasodilator Agents | 2019 |
Utilization of a micellar matrix for simultaneous spectrofluorimetric estimation of alfuzosin hydrochloride and vardenafil hydrochloride.
Topics: Humans; Micelles; Quinazolines; Spectrometry, Fluorescence; Tablets; Vardenafil Dihydrochloride | 2022 |